Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome
Sponsor: Fondazione Telethon
Summary
This is an open-label, single arm study to evaluate the cryopreserved formulation of OTL-103 Gene Therapy. OTL-103 consists of autologous CD34+ hematopoietic stem cells in which the gene encoding for the Wiskott-Aldrich Syndrome is introduced by means of a third generation lentiviral vector.
Official title: A Single Arm, Open-label Clinical Trial of Hematopoietic Stem Cell Gene Therapy With Cryopreserved Autologous CD34+ Cells Transduced With Lentiviral Vector Encoding WAS cDNA in Subjects With Wiskott-Aldrich Syndrome (WAS)
Key Details
Gender
All
Age Range
Any - 65 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2019-01-21
Completion Date
2027-09
Last Updated
2025-09-29
Healthy Volunteers
No
Conditions
Interventions
OTL-103
Autologous hematopoietic stem cells collected from mobilized peripheral blood transduced ex vivo with a lentiviral vector encoding the WAS cDNA
Locations (2)
Children's Healthcare of Atlanta, Inc
Atlanta, Georgia, United States
Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET)
Milan, Italy